Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 603 All time
- Disclosed funding
- $28.7B 480 disclosed amounts
- Median round
- $17M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
BIOMAKERS analyzes clinical and genomic information. | $8M | Undisclosed | Biotech | United States | Investors | |
Cancilico develops AI diagnostic software for hematology. | €2.5M | Seed | Biotech, Healthtech | Germany | Investors | |
| AI Anzen IndustriesCompany profile Anzen Industries, now operating as Tera, develops modular cell-free enzyme reactors for manufacturing high-value chemicals. Anzen Industries, now operating as Tera, develops modular cell-free enzyme reactors for manufacturing high-value chemicals. | $2.2M | Pre-seed | Biotech | United States | Investors | |
| C Develops cell therapy platform for liver disease | $60M | Series A | Biotech | United States | Investors | |
| S SableCompany profile Develops high-performance topical solutions for body contouring and sustained aesthetic results Develops high-performance topical solutions for body contouring and sustained aesthetic results | Undisclosed | Pre-SeedPre-seed | Biotech | United States | Investors | |
| TM Transition Metal SolutionsCompany profile Develops custom chemical additives to enhance wild microbial communities for metal extraction Develops custom chemical additives to enhance wild microbial communities for metal extraction | $6M | Seed | Biotech, Industrial tech | United States | Investors | |
| CT Caldera TherapeuticsCompany profile Develops bispecific antibody CLD-423 for inflammatory bowel disease Develops bispecific antibody CLD-423 for inflammatory bowel disease | $37.5M | Series A1Series A | Biotech | United States | Investors | |
| RL Develops AI operating system for oncology workflows | $11.1M | Series A | Biotech, AI | United States | Investors | |
| AB Provider of human induced pluripotent stem cell (iPSC) technologies | $2.8M | Undisclosed | Biotech | United Kingdom | Investors | |
Vivere OncotherapiesCompany profile Vivere Oncotherapies develops cancer treatments designed to activate immune recognition and destruction of cancer cells. Vivere Oncotherapies develops cancer treatments designed to activate immune recognition and destruction of cancer cells. | $10M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Delix Therapeutics, Alethio Therapeutics, Estuary Biotherapeutics
27rounds6led - 2Eli Lilly and Company
Oyster Therapeutics, BigHat Biosciences, Circle Pharma, Inc.
16rounds0led - 3Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
16rounds1led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
16rounds1led - 5OrbiMed
Dren Bio, Star Therapeutics, Leal Therapeutics
12rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.